Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Features
AMS Features
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis
By
Aesthetic Multispecialty Society
posted
Mar 18, 2021 10:15 AM
0
Recommend
.
0 comments
0 views
Related Content
Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events
Aesthetic Multispecialty Society
Added Apr 22, 2020
Blog Entry
PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines
Aesthetic Multispecialty Society
Added Feb 22, 2021
Blog Entry
New evidence-based resources to guide treatment of plaque psoriasis
Aesthetic Multispecialty Society
Added Sep 08, 2021
Blog Entry
Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year
Aesthetic Multispecialty Society
Added Apr 03, 2020
Blog Entry
Effectiveness of cyclosporine A in patients with moderate to severe plaque psoriasis in a real-life clinical setting in Italy: the TRANSITION study
Aesthetic Multispecialty Society
Added Apr 30, 2020
Blog Entry
Permalink
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic